Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant paclitaxel + carboplatin chemoradiation feasibility study in gastric adenocarcinoma
NL-OMON24232Active, not recruiting
- Sponsor
- University Medical Center Groningen
- Start
- Sep 2007
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of paclitaxel and carboplatin in gastric adenocarcinoma and gastric cancer (GC), sponsored by University Medical Center Groningen. Primary endpoints: Feasibility and Delay in curative resection. Started Sep 2007; status: active, not recruiting.
02
Drugs
paclitaxelcarboplatin
03
Conditions
gastric adenocarcinomagastric cancer (GC)
Beyond the preview
Go deeper on NL-OMON24232.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON24232.